{
    "organizations": [],
    "uuid": "9523a5f923d2b2290bfa4f1d5bd037d0f57eb3f6",
    "author": "Cara Lombardo",
    "url": "https://www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153",
    "ord_in_thread": 0,
    "title": "Celgene to Buy Juno Therapeutics for $9 Billion",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Celgene Corp. on Monday said it agreed to buy Juno Therapeutics Inc. for $87 a share in cash, or about $9 billion, in a move that will expand Celgeneâ€™s portfolio of blood-cancer drugs.\nThe Wall Street Journal reported last week the two companies were in deal talks.\n\nThe deal will add a lymphoma treatment, expected to gain regulatory approval... To Read the Full Story Subscribe Sign In",
    "published": "2018-01-22T14:29:00.000+02:00",
    "crawled": "2018-01-22T16:53:15.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "celgene",
        "monday",
        "said",
        "agreed",
        "buy",
        "juno",
        "therapeutic",
        "share",
        "cash",
        "billion",
        "move",
        "expand",
        "celgene",
        "portfolio",
        "drug",
        "wall",
        "street",
        "journal",
        "reported",
        "last",
        "week",
        "two",
        "company",
        "deal",
        "talk",
        "deal",
        "add",
        "lymphoma",
        "treatment",
        "expected",
        "gain",
        "regulatory",
        "approval",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}